Northwest Biotherapeutics, Inc.
NWBO
$0.25
$0.00-0.83%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 236.00% | 52.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 236.00% | 52.67% | |||
| Cost of Revenue | -25.45% | 0.27% | |||
| Gross Profit | 32.66% | 0.67% | |||
| SG&A Expenses | 21.95% | -5.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.37% | -2.62% | |||
| Operating Income | 5.70% | 3.11% | |||
| Income Before Tax | 103.17% | -74.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 105.17% | -74.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 105.17% | -74.46% | |||
| EBIT | 5.70% | 3.11% | |||
| EBITDA | 7.88% | 3.20% | |||
| EPS Basic | 113.74% | -63.96% | |||
| Normalized Basic EPS | 32.58% | -64.81% | |||
| EPS Diluted | 96.50% | -80.18% | |||
| Normalized Diluted EPS | 32.58% | -64.81% | |||
| Average Basic Shares Outstanding | 2.90% | 3.75% | |||
| Average Diluted Shares Outstanding | 2.90% | 3.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||